In this sense, these new data may suggest, in M1c patients, the alteration in IL-12 signaling in their NK cells, as well as lower NK cell response to IL-12 or IL-12 and IL-18 in combination, the potential immunotherapy of MM patients. This evidence concerns the gene IL18 and Miyoshi myopathy.